After Hours
$
60.00
Change
+2.10 +3.63%
Volume
Volume 30,591
Jun 27, 2022, 6:12 p.m.
Quotes are delayed by 20 min
Today's close
$ 55.62
$ 57.90
Change
+2.28 +4.10%
Day low
Day high
$55.97
$59.04

52 week low
52 week high
$28.40
$66.00

Market cap
$5.25B
Average volume
872,018
P/E ratio
N/A
Rev. per Employee
$163,678
EPS
-3.62
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on ITCI
-
Intra-Cellular Therapies started at buy with $75 stock price target at UBS
- Tomi Kilgore
-
The FDA Is About to Make Some Major Drug Decisions
- Barron's Online
-
Intra-Cellular Therapies downgraded to neutral from overweight at J.P. Morgan
- Tomi Kilgore
-
Intra-Cellular Therapies stock price target raised to $65 vs. $29 at Canaccord
- Ciara Linnane
-
Intra-Cellular Therapies reiterated as buy at Canaccord
- Ciara Linnane
-
Intra-Cellular Therapies gets FDA approval for schizophrenia treatment
- Ciara Linnane
-
Intra-Cellular Therapies stock soars 42% premarket
- Ciara Linnane
-
Intra-Cellular Therapies shares slide 7% after resuming trade following halt.
- Ciara Linnane
-
Intra-Cellular announces positive results in late-stage trial of treatment for bipolar depression
- Ciara Linnane
-
Intra-Cellular Therapies and Sol-Gel Technologies halted for news pending
- Ciara Linnane
-
Intra-Cellular Therapies started at overweight with $25 stock price target at J.P. Morgan
- Tomi Kilgore
-
Intra-Cellular Therapies upgraded to buy from hold at SunTrust RH
- Tomi Kilgore
- Loading more headlines...
Analyst Ratings
-
Benzinga's Top Upgrades, Downgrades For December 15, 2017
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For August 30, 2017
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For August 24, 2017
- Benzinga.com
Other News on ITCI
-
Intra-Cellular Therapies: A Dramatic Story
- Seeking Alpha
-
Wasatch Core Growth Fund Q1 2022 Commentary
- Seeking Alpha
-
Wasatch Small Cap Value Fund Q1 2022 Commentary
- Seeking Alpha
-
Wasatch Ultra Growth Fund Q1 2022 Commentary
- Seeking Alpha
-
Why Intra-Cellular Therapies Stock Rose 21.4% This Week
- Motley Fool
-
Why Intra-Cellular Therapies Trounced the S&P 500 Today
- Motley Fool
-
10-Q: INTRA-CELLULAR THERAPIES, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Intra-Cellular Therapies Q1 2022 Earnings Preview
- Seeking Alpha
-
Notable earnings before Tuesday's open
- Seeking Alpha
-
- Seeking Alpha
-
Vanda: A Dual Growth And Value Player
- Seeking Alpha
-
Intra-Cellular: Not Participating In A Bear Market
- Seeking Alpha
- Loading more headlines...
Press Releases on ITCI
-
What Stocks To Buy This Week? 4 Biotech Stocks To Know
- StockMarket.com
-
Intra-Cellular Therapies Inc. (ITCI): The Winning Streak Continues
- Investor Brand Network
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
- GlobeNewswire
-
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
- Financial News Media
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com